40.67

0.57% 0.2807

Ptc Therapeutics Inc (PTCT)

Overview News Price History Option Chain Financials Why PTCT Down? Discussions Forecast

Ptc Therapeutics Inc stock is traded at $40.67, with a volume of 108.93K. It is up +0.57% in the last 24 hours and up +15.73% over the past month. PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.

Previous Close:

$40.39

Open:

$40.36

24h Volume:

108.93K

Relative Volume:

0.17

Market Cap:

$3.13B

Revenue:

$900.45M

Net Income/Loss:

$-479.52M

P/E Ratio:

-4.7018

EPS:

-8.65

Net Cash Flow:

$-230.14M

1W Performance:

-4.42%

1M Performance:

+15.73%

6M Performance:

+23.05%

1Y Performance:

+107.99%

1-Day Range:

$39.89

$41.08

1-Week Range:

$39.41

$42.98

52-Week Range:

$18.15

$43.40

Ptc Therapeutics Inc Stock (PTCT) Company Profile

Name

Ptc Therapeutics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

(908) 222-7000

Address

500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ

Employee

995

Twitter

@PTCBio

Next Earnings Date

2024-11-07

Latest SEC Filings

PTCT's Discussions on Twitter

Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Dec-08-23	Initiated	Wells Fargo	Overweight
Oct-30-23	Upgrade	Oppenheimer	Perform → Outperform
Oct-27-23	Downgrade	Citigroup	Neutral → Sell
Oct-06-23	Downgrade	Truist	Buy → Hold
Sep-18-23	Downgrade	Citigroup	Buy → Neutral
Sep-15-23	Downgrade	Raymond James	Outperform → Underperform
Mar-17-23	Initiated	SVB Securities	Market Perform
Dec-14-22	Initiated	Goldman	Sell
Sep-12-22	Initiated	Jefferies	Buy
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight
Sep-01-22	Initiated	Citigroup	Buy
Apr-04-22	Resumed	Cantor Fitzgerald	Overweight
Oct-18-21	Downgrade	BofA Securities	Neutral → Underperform
Apr-26-21	Resumed	Credit Suisse	Neutral
Mar-29-21	Upgrade	RBC Capital Mkts	Underperform → Sector Perform
Feb-12-21	Downgrade	BofA Securities	Buy → Neutral
Jan-05-21	Upgrade	Citigroup	Neutral → Buy
Nov-30-20	Downgrade	RBC Capital Mkts	Sector Perform → Underperform
Oct-30-20	Downgrade	Citigroup	Buy → Neutral
Oct-28-20	Initiated	UBS	Neutral
Oct-07-20	Upgrade	JP Morgan	Neutral → Overweight
Aug-25-20	Initiated	Raymond James	Outperform
Apr-09-20	Upgrade	Citigroup	Neutral → Buy
Feb-20-20	Downgrade	Citigroup	Buy → Neutral
Feb-20-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-12-19	Initiated	SunTrust	Buy
May-13-19	Upgrade	BofA/Merrill	Neutral → Buy
Apr-11-19	Initiated	Bernstein	Outperform
Oct-03-18	Upgrade	BofA/Merrill	Underperform → Neutral
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight
Jul-19-18	Initiated	Credit Suisse	Outperform
Jun-18-18	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Apr-04-18	Downgrade	Barclays	Equal Weight → Underweight
Jan-29-18	Resumed	RBC Capital Mkts	Sector Perform
Nov-16-17	Upgrade	JP Morgan	Underweight → Neutral
Oct-26-17	Downgrade	BofA/Merrill	Neutral → Underperform
Oct-09-17	Downgrade	JP Morgan	Neutral → Underweight

View All

Ptc Therapeutics Inc Stock (PTCT) Latest News

Nov 04, 2024

FDA Accepts Resubmission of Translarna NDA for Duchenne - Managed Healthcare Executive

Oct 30, 2024

PTC Therapeutics (NASDAQ:PTCT) Hits New 12-Month HighHere's What Happened - MarketBeat

Oct 30, 2024

PTC Therapeutics (NASDAQ:PTCT) grows 8.1% this week, taking one-year gains to 127% - Yahoo Finance

Oct 30, 2024

PTC Therapeutics Announces FDA Acceptance of Translarna™ NDA Resubmission - cnhinews.com

Oct 30, 2024

Oct 29, 2024

PTC to ask for FDA approval of vatiquinone for FA by year’s end - Friedreich's Ataxia News

Oct 29, 2024

Oct 27, 2024

Assenagon Asset Management S.A. Has $18.27 Million Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

Oct 27, 2024

Oct 26, 2024

PTC Therapeutics sees positive long-term results on vatiquinone for Friedreich ataxia - MSN

Oct 26, 2024

Oct 25, 2024

PTCTPTC Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Oct 25, 2024

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Citizentribune

Oct 25, 2024

Oct 24, 2024

PTC Therapeutics (NASDAQ:PTCT) Sets New 52-Week HighHere's What Happened - MarketBeat

Oct 24, 2024

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial Results - StockTitan

Oct 24, 2024

Objective long/short (PTCT) Report - Stock Traders Daily

Oct 24, 2024

Oct 23, 2024

PTC Therapeutics (NASDAQ:PTCT) Shares Up 4.5%Should You Buy? - MarketBeat

Oct 23, 2024

Oct 19, 2024

Will PTC Therapeutics (PTCT) Report Negative Q3 Earnings? What You Should Know - MSN

Oct 19, 2024

Oct 18, 2024

PTC Therapeutics faces CHMP opposition on drug renewal By Investing.com - Investing.com Australia

Oct 18, 2024

State Street Corp's Strategic Acquisition in PTC Therapeutics Inc - GuruFocus.com

Oct 18, 2024

PTC Therapeutics faces CHMP opposition on drug renewal - Investing.com India

Oct 18, 2024

PTC Therapeutics: CHMP Again Recommends Against Translarna Renewal - MarketWatch

Oct 18, 2024

PTC rebuffed again by EMA; Novartis licenses China-based biotech’s cancer drug - Yahoo Finance

Oct 18, 2024

CHMP Maintains Negative Opinion on Translarna™ Reexamination - Citizentribune

Oct 18, 2024

Oct 17, 2024

Global Leigh Syndrome Treatment Market Dynamics and Future - openPR

Oct 17, 2024

Oct 15, 2024

Brokerages Set PTC Therapeutics, Inc. (NASDAQ:PTCT) PT at $40.08 - MarketBeat

Oct 15, 2024

Muscular Dystrophy Treatment Market Transformative Trends: - openPR

Oct 15, 2024

Oct 14, 2024

PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results - StockTitan

Oct 14, 2024

PTC Therapeutics brain disorder therapy granted FDA review - MSN

Oct 14, 2024

Leigh Syndrome Market to Rise by 2034 | PTC Therapeutics, Taysha - openPR

Oct 14, 2024

Leiomyosarcoma Clinical Trials 2024: FDA Approval, - openPR

Oct 14, 2024

Becker Muscular Dystropy Market Is in Huge Demand:Italfarmaco Spa, Milo Biotechnology Llc, Ptc Therapeutics Inc, Reverag – உங்கள் குரல் - உங்கள் குரல்

Oct 14, 2024

Oct 13, 2024

Becker Muscular Dystropy Market Is in Huge Demand:Italfarmaco Spa, Milo Biotechnology Llc, Ptc Therapeutics Inc, Reverag – IndiaPolitics.com - IndiaPolitics.com

Oct 13, 2024

PTC Therapeutics, Inc. (NASDAQ:PTCT) Short Interest Down 18.2% in September - MarketBeat

Oct 13, 2024

Learn to Evaluate (PTCT) using the Charts - Stock Traders Daily

Oct 13, 2024

SG Americas Securities LLC Makes New Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat

Oct 13, 2024

Oct 12, 2024

PTC Therapeutics (FRA:BH3) Forward Dividend Yield % : 0.00% (As of Oct. 12, 2024) - GuruFocus.com

Oct 12, 2024

PTC Therapeutics (FRA:BH3) Earnings per Share (Diluted) : €-5.84 (TTM As of Jun. 2024) - GuruFocus.com

Oct 12, 2024

PTC Therapeutics (FRA:BH3) Float Percentage Of Total Shares Outstanding : 64.19% (As of Oct. 12, 2024) - GuruFocus.com

Oct 12, 2024

Oct 11, 2024

PTC Therapeutics (NASDAQ:PTCT) Given New $45.00 Price Target at Morgan Stanley - MarketBeat

Oct 11, 2024

PTC Therapeutics, Inc. (NASDAQ:PTCT) to Post FY2025 Earnings of ($5.47) Per Share, William Blair Forecasts - MarketBeat

Oct 11, 2024

Oct 10, 2024

PTC Therapeutics (NASDAQ:PTCT) Shares Gap DownShould You Sell? - MarketBeat

Oct 10, 2024

Long-Term Benefits Put PTC Friedreich’s Ataxia Drug Back On Track - Scrip

Oct 10, 2024

Raymond James Initiates Coverage on PTC Therapeutics (NASDAQ:PTCT) - MarketBeat

Oct 10, 2024

PTC Therapeutics stock rated Market Perform by Raymond James - Investing.com UK

Oct 10, 2024

Oct 09, 2024